Canonical mutations during pancreatic carcinogenesis (e.g., KRAS, TP53, SMAD4, and CDKN2A), using this method, were efficiently detected in the PJ of PDAC/IPMN patients, proving useful in the evaluation of patients undergoing pancreatic surveillance [120]. Here, KRAS is linked to pancreatic intraductal papillary-mucinous neoplasm.